Literature DB >> 21764155

Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis.

Arnt V Kristen1, Sabine Haufe, Stefan O Schonland, Ute Hegenbart, Philipp A Schnabel, Christoph Röcken, Stefan Hardt, Peter Lohse, Anthony D Ho, Uwe Haberkorn, Thomas J Dengler, Klaus Altland, Hugo A Katus.   

Abstract

BACKGROUND: Senile systemic amyloidosis (SSA) is a common aging phenomenon in the elderly population. Nevertheless, pre-mortem diagnosis of SSA is rare. Thus, data on clinical characterization and disease severity are limited.
METHODS: 36 consecutive SSA patients (71.6 [64.7-82.7]years) were evaluated by electrocardiography, echocardiography, laboratory tests, and (99m)Technetium-3,3-diphosphono-1,2-propanodicarboxylic acid ((99m)Tc-DPD) scintigraphy (n=20).
RESULTS: In addition to cardiac involvement, amyloid deposition was found in rectum (n=6), peripheral nerves (n=2), and urinary bladder (n=2). Five patients showed low voltage pattern. Thickness of interventricular septum (IVS) was 20 [12-27]mm. LV longitudinal function was diminished (TDI-s 5 [3-11] cm/s; MAPSE 6.5 [2.5-19]mm; TAPSE 12.5 [2-24]mm). LV systolic function (LV-EF<45%) was markedly decreased in 19 patients. Plasma levels of troponin T (0.05 [0.01-0.23]µg/L) and NT-proBNP (4318 [205-16597]ng/L) were elevated. (99m)Tc-DPD heart retention was 7.8 [2.4-11.0]% and correlated with MAPSE (ρ=-0.716; p=0.0018), TAPSE (ρ=-0.491; p<0.05), and IVS (ρ=0.556; p=0.0153). Heart-to-body ratio correlated with MAPSE (ρ=-0.771; p=0.0018), IVS (ρ=0.603; p=0.0086). Twelve patients died during follow-up of 27.4 [0.1-106.2]months. Exclusively (99m)Tc-DPD heart retention, diastolic dysfunction and in trend MAPSE were associated with patient's outcome. Interestingly, risk predictors that were well established in patients with AL amyloidosis were not predictive for survival in patients with SSA.
CONCLUSIONS: This study gave first evidence that (99m)Tc-DPD HR may be capable to display the extent of cardiac amyloid deposition. Moreover, this study suggested that (99m)Tc-DPD HR, diastolic dysfunction and in trend MAPSE are associated with poor outcome. Nevertheless, these findings need to be established in a larger prospective trial. Crown
Copyright © 2011. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21764155     DOI: 10.1016/j.ijcard.2011.06.123

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  11 in total

1.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2019-12       Impact factor: 5.952

Review 2.  Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies.

Authors:  Ilia G Halatchev; Jingsheng Zheng; Jiafu Ou
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 3.  Recent advances in the noninvasive strategies of cardiac amyloidosis.

Authors:  Lei Zhao; Quan Fang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 4.  Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology.

Authors:  Mathew S Maurer
Journal:  Am J Med       Date:  2015-06-17       Impact factor: 4.965

5.  Transthyretin Cardiac Amyloidosis in Older Adults: Optimizing Cardiac Imaging to the Corresponding Diagnostic and Management Goal.

Authors:  Adam Castaño; Daniel K Manson; Mathew S Maurer; Sabahat Bokhari
Journal:  Curr Cardiovasc Risk Rep       Date:  2017-04-25

Review 6.  Nuclear imaging modalities for cardiac amyloidosis.

Authors:  Sabahat Bokhari; Reehan Shahzad; Adam Castaño; Mathew S Maurer
Journal:  J Nucl Cardiol       Date:  2014-02       Impact factor: 5.952

Review 7.  Estimating the Gender Distribution of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis.

Authors:  Florint Kroi; Nils Fischer; Ana Gezin; Mahmoud Hashim; Mark Hermannes Rozenbaum
Journal:  Cardiol Ther       Date:  2020-12-14

8.  Speckle Tracking and Transthyretin Amyloid Cardiomyopathy.

Authors:  Alexandre Marins Rocha; Suzane Garcia Ferreira; Marcelo Souto Nacif; Mario Luiz Ribeiro; Marcos Raimundo Gomes de Freitas; Cláudio Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2016-12-19       Impact factor: 2.000

9.  Senile systemic amyloidosis: clinical features at presentation and outcome.

Authors:  Jennifer H Pinney; Carol J Whelan; Aviva Petrie; Jason Dungu; Sanjay M Banypersad; Prayman Sattianayagam; Ashutosh Wechalekar; Simon D J Gibbs; Christopher P Venner; Nancy Wassef; Carolyn A McCarthy; Janet A Gilbertson; Dorota Rowczenio; Philip N Hawkins; Julian D Gillmore; Helen J Lachmann
Journal:  J Am Heart Assoc       Date:  2013-04-22       Impact factor: 5.501

10.  Green tea halts progression of cardiac transthyretin amyloidosis: an observational report.

Authors:  Arnt V Kristen; Stephanie Lehrke; Sebastian Buss; Derliz Mereles; Henning Steen; Philipp Ehlermann; Stefan Hardt; Evangelos Giannitsis; Rupert Schreiner; Uwe Haberkorn; Philipp A Schnabel; Reinhold P Linke; Christoph Röcken; Erich E Wanker; Thomas J Dengler; Klaus Altland; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2012-05-15       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.